Key Takeaway: The article discusses the findings from the US Arimoclomol Expanded Access Program related to NPC1 genotypes in patients with Niemann-Pick Disease Type C. It provides an overview of the program's objectives and the implications of the findings for treatment. However, specific results or conclusions from the analysis are not detailed in the text.
Price reaction · baseline $9.71 (2026-04-09 close) · hit after-hours · clean, no other ZVRA news in the window
day 0 close · peak
-2.5%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+71%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Lead asset
KP415
Phase 3 · ADHD
Full Press Release Details
• Overview
• Events & Presentations
• Stock Information
• - Stock Quote & Chart
• - Historic Stock Lookup
• - Analyst Coverage
• Press Releases
• Corporate Governance
• - Committee Composition
• - IRS – Required Disclosures
• Financials
• - SEC Filings
• - Quarterly Results
• - Annual Reports & Proxy
• State Compliance
• Email Alerts
• FAQs
Analysis of NPC1 Genotypes: Findings From the US Arimoclomol Expanded Access Program for Niemann-Pick Disease Type C